دورية أكاديمية
Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy
| العنوان: | Progressive, Long-Term Hearing Loss in Congenital CMV Disease After Ganciclovir Therapy |
|---|---|
| المؤلفون: | Lanzieri, Tatiana M, Caviness, Alison Chantal, Blum, Peggy, Demmler-Harrison, Gail, Ahmed, Shahzad, Baer, Hanna, Bhatt, Amit R, Brown, Frank, Catlin, Francis, Caviness, Alison C, Coats, David K, Edmonds, Jane C, Flores, Marily, Franklin, Daniel, Gandaria, Cindy, Greer, Jewel, Griesser, Carol, Hussein, Mohamed A, Iovino, Isabella, Istas, Allison, Jin, Haoxing (Douglas), Kelinske, Mary K, Klingen, Joseph T, Laurente, Antone, Littman, Thomas, Murphy, Mary, Miller, Jerry, Nelson, Christopher, Noyola, Daniel, Paysse, Evelyn A, Percy, Alan, Reis, Sara, Reynolds, Ann, Rozelle, Judith, Smith, O’Brien, Steinkuller, Paul, Turcich, Marie, Vinson, Sherry Sellers, Voigt, Robert G, Walmus, Bethann, Williams, Jill, Williamson, Daniel, Yen, Kimberly G, Yow, Martha D, Demmler-Harrison, Gail J |
| المساهمون: | National Institutes of Health |
| المصدر: | Journal of the Pediatric Infectious Diseases Society ; volume 11, issue 1, page 16-23 ; ISSN 2048-7207 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Infectious Diseases, General Medicine, Pediatrics, Perinatology and Child Health |
| الوصف: | Background Long-term hearing outcomes among children with symptomatic congenital cytomegalovirus (CMV) disease who received 6-week ganciclovir therapy early in life are unknown. Methods Longitudinal study of 76 children with symptomatic congenital CMV disease, born 1983-2005, who were categorized into three groups: group A treated with ganciclovir; group B untreated who had microcephaly, chorioretinitis, or sensorineural hearing loss (SNHL; ≥25 dB) diagnosed in the first month of life (congenital); and group C untreated who did not meet criteria for group B. Results Patients in groups A (n = 17), B (n = 27), and C (n = 32) were followed to median age of 13, 11, and 13 years, respectively. In group A, patients received ganciclovir for median of 40 (range, 11-63) days; 7 (41%) had grade 3 or 4 neutropenia. Congenital SNHL was diagnosed in 11 (65%) patients in group A, 15 (56%) in group B, and none in group C. Early-onset SNHL was diagnosed between ages ≥1-12 months in an additional 4 (24%), 6 (22%), and 8 (25%) patients in groups A, B, and C, respectively. By the end of follow-up, 12 (71%), 16 (59%), and 7 (22%) of patients in groups A, B, and C, respectively, had severe (>70 dB) SNHL in the better-hearing ear. Conclusions In this study, most patients with symptomatic congenital CMV disease and congenital or early-onset SNHL eventually developed hearing loss severe enough to have been potential candidates for cochlear implantation, with or without 6-week ganciclovir therapy. Understanding long-term hearing outcomes of patients treated with 6-month oral valganciclovir (current standard of care) is needed. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/jpids/piab095 |
| الإتاحة: | https://doi.org/10.1093/jpids/piab095Test https://academic.oup.com/jpids/article-pdf/11/1/16/48076482/piab095.pdfTest |
| رقم الانضمام: | edsbas.8A80CE5E |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/jpids/piab095 |
|---|